back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-06-05 11:47 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-553,744 vol |
0 | |
| Filed 2024-06-05 11:47 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$-6,300
-300 vol $21.00 each |
0 | |
| Filed 2021-02-08 18:56 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+114,000 vol |
553,744 | |
| Filed 2020-07-03 19:34 Tx date 2020-06-26 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
+351,921 vol |
439,744 | |
| Filed 2020-07-03 19:33 Tx date 2020-06-26 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
-351,921 vol |
0 | |
| Filed 2020-07-03 19:32 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
-351,921 vol |
||
| Filed 2020-07-03 19:32 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
+351,921 vol |
||
| Filed 2020-07-03 17:31 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
+351,921 vol |
439,744 | |
| Filed 2020-07-03 17:31 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
+351,921 vol |
||
| Filed 2020-07-03 17:30 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
-351,921 vol |
||
| Filed 2020-07-03 17:30 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
36 - Conversion or exchange
|
-351,921 vol |
0 | |
| Filed 2020-07-03 17:29 Tx date 2020-06-30 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,100
+300 vol $17.00 each |
300 | |
| Filed 2020-07-03 17:28 Tx date 2020-06-25 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-07-03 17:26 Tx date 2020-06-25 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
87,823 | ||
| Filed 2020-07-03 17:26 Tx date 2020-06-25 |
$
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
351,921 |